Elisabeth M Dykens1, Jennifer Miller2, Moris Angulo3, Elizabeth Roof1, Michael Reidy4, Hind T Hatoum5, Richard Willey4, Guy Bolton4, Paul Korner4. 1. Kennedy Center for Research on Human Development, Vanderbilt University, Nashville, Tennessee, USA. 2. Division of Pediatric Endocrinology, University of Florida, College of Medicine, Gainesville, Florida, USA. 3. Department of Pediatrics, Winthrop University Hospital, Mineola, New York, USA. 4. Ferring Pharmaceuticals Inc., Parsippany, New Jersey, USA. 5. Hind T. Hatoum & Company, Chicago, Illinois, USA.
Abstract
BACKGROUND: Prader-Willi syndrome (PWS) is a genetic neurodevelopmental disorder of life-threatening hyperphagia, obesity, intellectual deficits, compulsivity, and other behavioral problems. The efficacy and safety of i.n. carbetocin, an oxytocin analog, was evaluated in a prospective, randomized, double-blinded trial in adolescents with PWS. METHODS:Eligible patients aged 10-18 years with genetically confirmed PWS were randomized (1:1) to i.n. carbetocin or placebo 3 times daily for 14 days. The primary efficacy endpoint was change in parent/caregiver-rated Hyperphagia in PWS Questionnaire-Responsiveness (HPWSQ-R) total score. Secondary efficacy endpoints included HPWSQ-R behavior, drive, and severity domains; clinician-rated HPWSQ; Children's Yale-Brown Obsessive-Compulsive Severity Scale; food domain of the Reiss Profile; and Clinical Global Impression-Improvement scale. Endpoints were assessed using analysis of covariance. Relationship between primary and secondary endpoints was assessed using Pearson correlation coefficients. Safety was assessed throughout the study. RESULTS: Demographics and clinical characteristics were similar between treatment groups (carbetocin, n = 17; placebo, n = 20). Patients receiving carbetocin had statistically significant reductions in HPWSQ-R total score at study end (-15.6) versus patients receiving placebo (-8.9; P = 0.029); several secondary efficacy endpoints also demonstrated significant differences (P < 0.05). Treatment effects for the primary and secondary endpoints were highly correlated (P ≤ 0.0001). Incidence of adverse events (AEs) was similar between treatment groups. CONCLUSION: I.n. carbetocin was well tolerated and improved hyperphagia and behavioral symptoms of PWS. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01968187FUNDING. The study was funded by Ferring Pharmaceuticals. Recruitment was aided by ongoing work in PWS performed through Eunice Kennedy Shriver National Institute of Child Health and Human Development grant U54 HD083211.
RCT Entities:
BACKGROUND:Prader-Willi syndrome (PWS) is a genetic neurodevelopmental disorder of life-threatening hyperphagia, obesity, intellectual deficits, compulsivity, and other behavioral problems. The efficacy and safety of i.n. carbetocin, an oxytocin analog, was evaluated in a prospective, randomized, double-blinded trial in adolescents with PWS. METHODS: Eligible patients aged 10-18 years with genetically confirmed PWS were randomized (1:1) to i.n. carbetocin or placebo 3 times daily for 14 days. The primary efficacy endpoint was change in parent/caregiver-rated Hyperphagia in PWS Questionnaire-Responsiveness (HPWSQ-R) total score. Secondary efficacy endpoints included HPWSQ-R behavior, drive, and severity domains; clinician-rated HPWSQ; Children's Yale-Brown Obsessive-Compulsive Severity Scale; food domain of the Reiss Profile; and Clinical Global Impression-Improvement scale. Endpoints were assessed using analysis of covariance. Relationship between primary and secondary endpoints was assessed using Pearson correlation coefficients. Safety was assessed throughout the study. RESULTS: Demographics and clinical characteristics were similar between treatment groups (carbetocin, n = 17; placebo, n = 20). Patients receiving carbetocin had statistically significant reductions in HPWSQ-R total score at study end (-15.6) versus patients receiving placebo (-8.9; P = 0.029); several secondary efficacy endpoints also demonstrated significant differences (P < 0.05). Treatment effects for the primary and secondary endpoints were highly correlated (P ≤ 0.0001). Incidence of adverse events (AEs) was similar between treatment groups. CONCLUSION: I.n. carbetocin was well tolerated and improved hyperphagia and behavioral symptoms of PWS. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01968187FUNDING. The study was funded by Ferring Pharmaceuticals. Recruitment was aided by ongoing work in PWS performed through Eunice Kennedy Shriver National Institute of Child Health and Human Development grant U54 HD083211.
Authors: David A Stevenson; Janalee Heinemann; Moris Angulo; Merlin G Butler; Jim Loker; Norma Rupe; Patrick Kendell; Carol L Clericuzio; Ann O Scheimann Journal: Am J Med Genet A Date: 2007-03-01 Impact factor: 2.802
Authors: Jennifer L Miller; Roy Tamura; Merlin G Butler; Virginia Kimonis; Carlos Sulsona; June-Anne Gold; Daniel J Driscoll Journal: Am J Med Genet A Date: 2017-03-30 Impact factor: 2.802
Authors: Jennifer A Bartz; Jamil Zaki; Niall Bolger; Eric Hollander; Natasha N Ludwig; Alexander Kolevzon; Kevin N Ochsner Journal: Psychol Sci Date: 2010-09-20
Authors: Eric A Storch; Tanya K Murphy; Gary R Geffken; Ohel Soto; Muhammad Sajid; Pam Allen; Jonathan W Roberti; Erin M Killiany; Wayne K Goodman Journal: Psychiatry Res Date: 2004-11-30 Impact factor: 3.222
Authors: Lisa C Burnett; Charles A LeDuc; Carlos R Sulsona; Daniel Paull; Richard Rausch; Sanaa Eddiry; Jayne F Martin Carli; Michael V Morabito; Alicja A Skowronski; Gabriela Hubner; Matthew Zimmer; Liheng Wang; Robert Day; Brynn Levy; Ilene Fennoy; Beatrice Dubern; Christine Poitou; Karine Clement; Merlin G Butler; Michael Rosenbaum; Jean Pierre Salles; Maithe Tauber; Daniel J Driscoll; Dieter Egli; Rudolph L Leibel Journal: J Clin Invest Date: 2016-12-12 Impact factor: 14.808
Authors: David A Stevenson; Janalee Heinemann; Moris Angulo; Merlin G Butler; Jim Loker; Norma Rupe; Patrick Kendell; Suzanne B Cassidy; Ann Scheimann Journal: J Pediatr Gastroenterol Nutr Date: 2007-08 Impact factor: 2.839
Authors: Samantha G Farris; Carmen P McLean; Page E Van Meter; Helen Blair Simpson; Edna B Foa Journal: J Clin Psychiatry Date: 2013-07 Impact factor: 4.384
Authors: Hermann L Müller; Maithé Tauber; Elizabeth A Lawson; Jale Özyurt; Brigitte Bison; Juan-Pedro Martinez-Barbera; Stephanie Puget; Thomas E Merchant; Hanneke M van Santen Journal: Nat Rev Dis Primers Date: 2022-04-21 Impact factor: 52.329
Authors: Robert M Haws; Gregory Gordon; Joan C Han; Jack A Yanovski; Guojun Yuan; Murray W Stewart Journal: Contemp Clin Trials Commun Date: 2021-05-03
Authors: A J Conley; T Berger; R Arias Del Razo; R F Cotterman; E Sahagún; L R Goetze; S Jacob; T A R Weinstein; M E Dufek; S P Mendoza; K L Bales Journal: Horm Behav Date: 2022-03-23 Impact factor: 3.492